Establishing Avastin-based therapy as essential for the first-line treatment of metastatic non-squamous NSCLC
Avastin: proven and consistent efficacy in first-line NSCLC
- NSCLC accounts for >80% of all cases of lung cancer and is diagnosed at an advanced stage in the majority of patients.1
- Tumour histology is of particular importance in selecting therapy for advanced NSCLC
- NSCLC consists of both squamous and non-squamous histologies, the majority of non-squamous cases being adenocarcinomas.2
- Chemotherapy (platinum doublets) is the most commonly used approach in the treatment of NSCLC, but outcomes with chemotherapy have reached a plateau.3
- Avastin, in combination with platinum-doublet chemotherapy, is approved for the first-line treatment of patients with unresectable, advanced, metastatic or recurrent non-squamous NSCLC.
- The proven efficacy and favourable safety profile of first-line Avastin has been demonstrated in two large, randomised phase III clinical trials
- Avastin delivers the longest survival time in non-squamous NSCLC
- Avastin has limited impact on the side effects of chemotherapy.
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.